Differential expression of PDE5 in failing and nonfailing human myocardium.
Shan X, Quaile MP, Monk JK et al.
Phosphodiesterase-5 (PDE-5) inhibitors are commonly used in the treatment of pulmonary arterial hypertension and their effects upon the pulmonary vasculature have been well described. PDE-5 expression has also been described in cardiomyocytes, and the use of PDE-5 inhibitors has been suggested to be of benefit in preventing cardiac hypertrophy, improving contractility and ventricular function (Nat Med 2005;11:214–22). In the present study, the authors examined PDE-5 expression in the right ventricles (RVs) of four control, non-failing ventricles and 20 patients with either mild or severe RV dysfunction in the presence of ischemic or non-ischemic cardiomyopathy.